Global Parkinson Disease Drug Market Overview And Scope:
Global Parkinson Disease Drug Market Size was estimated at USD 5842.33 million in 2022 and is projected to reach USD 8411.12 million by 2028, exhibiting a CAGR of 6.26% during the forecast period.
The Global Parkinson Disease Drug Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Parkinson Disease Drug utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Kyowa Hakko Kirin Pharma, Astellas Pharma, Desitin Arzneimittel, Endo Pharmaceuticals, F.Hoffmann-La Roche, H.Lundbeck, Valeant, Apokyn, Orion, Stada Arzneimittel, US WorldMeds, Bausch Health
Global Parkinson Disease Drug Market Segmentation
By Type, Parkinson Disease Drug market has been segmented into:Sinemet-CR
Trastal
Madopar
COMT Inhibitor
Other
By Application, Parkinson Disease Drug market has been segmented into:
Under 40 Years Old
40-65 Years Old
Above 65 Years Old
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Parkinson Disease Drug market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Parkinson Disease Drug market.
Top Key Players Covered in Parkinson Disease Drug market are:
Merck
Akorn
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Hakko Kirin Pharma
Astellas Pharma
Desitin Arzneimittel
Endo Pharmaceuticals
F.Hoffmann-La Roche
H.Lundbeck
Valeant
Apokyn
Orion
Stada Arzneimittel
US WorldMeds
Bausch Health
Objective to buy this Report:
1. Parkinson Disease Drug analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Parkinson Disease Drug market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Parkinson Disease Drug Market by Type
5.1 Parkinson Disease Drug Market Overview Snapshot and Growth Engine
5.2 Parkinson Disease Drug Market Overview
5.3 Sinemet-CR
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Sinemet-CR: Geographic Segmentation
5.4 Trastal
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Trastal: Geographic Segmentation
5.5 Madopar
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Madopar: Geographic Segmentation
5.6 COMT Inhibitor
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 COMT Inhibitor: Geographic Segmentation
5.7 Other
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Other: Geographic Segmentation
Chapter 6: Parkinson Disease Drug Market by Application
6.1 Parkinson Disease Drug Market Overview Snapshot and Growth Engine
6.2 Parkinson Disease Drug Market Overview
6.3 Under 40 Years Old
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Under 40 Years Old: Geographic Segmentation
6.4 40-65 Years Old
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 40-65 Years Old: Geographic Segmentation
6.5 Above 65 Years Old
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Above 65 Years Old: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Parkinson Disease Drug Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Parkinson Disease Drug Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Parkinson Disease Drug Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 MERCK
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 AKORN
7.4 GSK
7.5 NOVARTIS
7.6 BOEHRINGER INGELHEIM
7.7 TEVA PHARMACEUTICAL
7.8 ABBVIE
7.9 KYOWA HAKKO KIRIN PHARMA
7.10 ASTELLAS PHARMA
7.11 DESITIN ARZNEIMITTEL
7.12 ENDO PHARMACEUTICALS
7.13 F.HOFFMANN-LA ROCHE
7.14 H.LUNDBECK
7.15 VALEANT
7.16 APOKYN
7.17 ORION
7.18 STADA ARZNEIMITTEL
7.19 US WORLDMEDS
7.20 BAUSCH HEALTH
Chapter 8: Global Parkinson Disease Drug Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Sinemet-CR
8.2.2 Trastal
8.2.3 Madopar
8.2.4 COMT Inhibitor
8.2.5 Other
8.3 Historic and Forecasted Market Size By Application
8.3.1 Under 40 Years Old
8.3.2 40-65 Years Old
8.3.3 Above 65 Years Old
Chapter 9: North America Parkinson Disease Drug Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Sinemet-CR
9.4.2 Trastal
9.4.3 Madopar
9.4.4 COMT Inhibitor
9.4.5 Other
9.5 Historic and Forecasted Market Size By Application
9.5.1 Under 40 Years Old
9.5.2 40-65 Years Old
9.5.3 Above 65 Years Old
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Parkinson Disease Drug Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Sinemet-CR
10.4.2 Trastal
10.4.3 Madopar
10.4.4 COMT Inhibitor
10.4.5 Other
10.5 Historic and Forecasted Market Size By Application
10.5.1 Under 40 Years Old
10.5.2 40-65 Years Old
10.5.3 Above 65 Years Old
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Parkinson Disease Drug Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Sinemet-CR
11.4.2 Trastal
11.4.3 Madopar
11.4.4 COMT Inhibitor
11.4.5 Other
11.5 Historic and Forecasted Market Size By Application
11.5.1 Under 40 Years Old
11.5.2 40-65 Years Old
11.5.3 Above 65 Years Old
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Parkinson Disease Drug Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Sinemet-CR
12.4.2 Trastal
12.4.3 Madopar
12.4.4 COMT Inhibitor
12.4.5 Other
12.5 Historic and Forecasted Market Size By Application
12.5.1 Under 40 Years Old
12.5.2 40-65 Years Old
12.5.3 Above 65 Years Old
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Parkinson Disease Drug Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Sinemet-CR
13.4.2 Trastal
13.4.3 Madopar
13.4.4 COMT Inhibitor
13.4.5 Other
13.5 Historic and Forecasted Market Size By Application
13.5.1 Under 40 Years Old
13.5.2 40-65 Years Old
13.5.3 Above 65 Years Old
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Parkinson Disease Drug Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Sinemet-CR
14.4.2 Trastal
14.4.3 Madopar
14.4.4 COMT Inhibitor
14.4.5 Other
14.5 Historic and Forecasted Market Size By Application
14.5.1 Under 40 Years Old
14.5.2 40-65 Years Old
14.5.3 Above 65 Years Old
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Parkinson Disease Drug Scope:
|
Report Data
|
Parkinson Disease Drug Market
|
|
Parkinson Disease Drug Market Size in 2025
|
USD XX million
|
|
Parkinson Disease Drug CAGR 2025 - 2032
|
XX%
|
|
Parkinson Disease Drug Base Year
|
2024
|
|
Parkinson Disease Drug Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Kyowa Hakko Kirin Pharma, Astellas Pharma, Desitin Arzneimittel, Endo Pharmaceuticals, F.Hoffmann-La Roche, H.Lundbeck, Valeant, Apokyn, Orion, Stada Arzneimittel, US WorldMeds, Bausch Health.
|
|
Key Segments
|
By Type
Sinemet-CR
Trastal
Madopar
COMT Inhibitor
Other
By Applications
Under 40 Years Old
40-65 Years Old
Above 65 Years Old
|
